'Time bomb' to fight cardiovascular disease developed
Researchers have developed a veritable "time bomb", a nanocontainer, which can increase the effectiveness of treatments against cardiovascular disease and reduce side effects
Many people die of cardiovascular disease caused by atherosclerosis each year.
Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects. Intravenous injection of a vasodilator (a substance that dilates blood vessels), such as nitroglycerin, dilates both the diseased vessels and the rest of our arteries.
Blood pressure can thus drop, which would limit the desired increased blood flow generated by vasodilatation of diseased vessels and needed for example during a heart attack.
But the nanocontainers developed by the researchers from UNIGE, HUG and the University of Basel have the ability to release their vasodilator content exclusively to diseased areas.
Though no biomarker specific to atherosclerosis has been identified, there is a physical phenomenon inherent to stenosis (the narrowing of blood vessels) known as shear stress. This force results from fluctuations in blood flow induced by the narrowing of the artery and runs parallel to the flow of blood.
It is by making use of this phenomenon that the team of researchers has developed the nanocontainer, which under pressure from the shear stress in stenosed arteries will release its vasodilator contents.
By rearranging the structure of certain molecules (phospholipids) in classic nanocontainers such as liposome, scientists were able to give them a lenticular shape as opposed to the normal spherical shape. In the form of a lens, the nanocontainer then moves through the healthy arteries without breaking.
This new nanocontainer is perfectly stable, except when subjected to the shear stress of stenosed arteries. And that''s exactly the intention of this technological advance. The vasodilator content is distributed only to the stenotic arteries, significantly increasing the efficacy of the treatment and reducing side effects.
“In brief, we exploited a previously unexplored aspect of an existing technology. This research offers new perspectives in the treatment of patients with cardiovascular disease,” explained Andreas Zumbuehl from the Department of Organic Chemistry at UNIGE.
Till Saxer of the Cardiology and General Internal Medicine Departments at HUG stated, “Nanomedicine is a discipline stemming from general nanoscience but which orients itself towards medical research. The interdisciplinary collaboration between chemistry, physics, basic science and clinical medicine in a highly technical environment could lead to a new era of research.”
“The nano component is present in all disciplines, but the most interesting aspect of nanomedicine is its overview allowing the development of clinical products that integrate this global medical point of view from the earliest onset of research projects,” added Bert Muller, Director of the Biomaterials Science Centre (BMC) at Basel.